News

iTeos Therapeutics Inc.: iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates
Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25 - Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC with ~200 patients anticipated in 2025 - Cash ...
Kura Oncology, Inc.: Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST
Phase 1 dose-escalation study to evaluate ziftomenib in combination with imatinib in patients with advanced GIST after imatinib failure - - Combination of ziftomenib and imatinib shows robust and dura ...
CERo announces SCRI as main site for trial of CER-1236 to treat AML
CERo Therapeutics has announced that Colorado Blood Cancer Institute’s (CBCI) Sarah Cannon Research Institute (SCRI), US, will be the main site for its Phase I study evaluating CER-1236 to treat acute ...
Zacks Investment Research on MSN3d
CytomX Gears Up to Report Q1 Earnings: Here's What to Expect
CytomX Therapeutics CTMX, a clinical-stage oncology company, is expected to beat first-quarter 2025 earnings when it reports ...
Obesity drug boom has a new pecking order
The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...
CURE4d
Dose-Limiting Toxicity Observation Phase Completed in CRS Trial for Lymphoma
In a Phase 1b/2a trial for lymphoma and cytokine release syndrome, the first group's dose-limiting toxicity observation ...